Literature DB >> 10751341

Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature.

B Stoelcker1, B Ruhland, T Hehlgans, H Bluethmann, T Luther, D N Männel.   

Abstract

Activation of endothelial cells, fibrin deposition, and coagulation within the tumor vasculature has been shown in vivo to correlate with the occurrence of tumor necrosis factor (TNF)-induced tumor necrosis in mice. In the present study we investigated which target cells mediate the TNF-induced necrosis in fibrosarcomas grown in wild type (wt), TNF receptor type 1-deficient (TNFRp55-/-), and TNF receptor type 2-deficient (TNFRp75-/-) mice. TNF administration resulted in tumor necrosis exclusively in wt and TNFRp75-/-, but not in TNFRp55-/- mice, indicating a dependence of TNF-mediated tumor necrosis on the expression of TNF receptor type 1. However, using wt and TNFRp55-/- fibrosarcomas in wt mice, we found that TNF-mediated tumor necrosis was completely independent of TNF receptor type 1 expression in tumor cells. Thus we could exclude any direct tumoricidal effect of TNF in this model. Soluble TNF induced leukostasis in wt and TNFRp75-/- mice but not in TNFRp55-/- mice. TNF-induced leukostasis in TNFRp55-/- mice was restored by adoptive bone marrow transplantation of wt hematopoietic cells, but TNF failed to induce tumor necrosis in these chimeric mice. Because TNF administration resulted in both activation and focal damage of tumor endothelium, TNF receptor type 1-expressing cells of the tumor vasculature, likely to be endothelial cells, appear to be target cells for mediating TNF-induced tumor necrosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10751341      PMCID: PMC1876893          DOI: 10.1016/S0002-9440(10)64986-3

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  26 in total

1.  Journal of the National Cancer Institute, Vol. 29, 1962: Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance.

Authors:  W E O'Malley; B Achinstein; M J Shear
Journal:  Nutr Rev       Date:  1988-11       Impact factor: 7.110

2.  Recombinant human tumor necrosis factor-alpha: thrombus formation is a cause of anti-tumor activity.

Authors:  K Shimomura; T Manda; S Mukumoto; K Kobayashi; K Nakano; J Mori
Journal:  Int J Cancer       Date:  1988-02-15       Impact factor: 7.396

3.  A p75 tumor necrosis factor receptor-specific mutant of murine tumor necrosis factor alpha expressed from an adenovirus vector induces an antitumor response with reduced toxicity.

Authors:  R A Marr; M Hitt; J Gauldie; W J Muller; F L Graham
Journal:  Cancer Gene Ther       Date:  1999 Sep-Oct       Impact factor: 5.987

4.  Detection of endotoxin in blood and other specimens by evaluation of photometrically registered LAL-reaction-kinetics in microtiter plates.

Authors:  B Ditter; K P Becker; R Urbaschek; B Urbaschek
Journal:  Prog Clin Biol Res       Date:  1982

5.  Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin.

Authors:  S A Gregory; J H Morrissey; T S Edgington
Journal:  Mol Cell Biol       Date:  1989-06       Impact factor: 4.272

6.  Mechanism of lipopolysaccharide-induced tumor necrosis: requirement for lipopolysaccharide-sensitive lymphoreticular cells.

Authors:  D N Männel; D L Rosenstreich; S E Mergenhagen
Journal:  Infect Immun       Date:  1979-05       Impact factor: 3.441

7.  Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity.

Authors:  M A Palladino; M R Shalaby; S M Kramer; B L Ferraiolo; R A Baughman; A B Deleo; D Crase; B Marafino; B B Aggarwal; I S Figari
Journal:  J Immunol       Date:  1987-06-01       Impact factor: 5.422

8.  Injury induces increase of von Willebrand factor in rat endothelial cells.

Authors:  M A Reidy; M Chopek; S Chao; T McDonald; S M Schwartz
Journal:  Am J Pathol       Date:  1989-04       Impact factor: 4.307

9.  Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas.

Authors:  P Nawroth; D Handley; G Matsueda; R De Waal; H Gerlach; D Blohm; D Stern
Journal:  J Exp Med       Date:  1988-08-01       Impact factor: 14.307

10.  Similarities of the anti-tumour actions of endotoxin, lipid A and double-stranded RNA.

Authors:  I Parr; E Wheeler; P Alexander
Journal:  Br J Cancer       Date:  1973-05       Impact factor: 7.640

View more
  17 in total

Review 1.  Repurposing Drugs for Cancer Radiotherapy: Early Successes and Emerging Opportunities.

Authors:  Mohammad K Khan; Tahseen H Nasti; Zachary S Buchwald; Ralph R Weichselbaum; Stephen J Kron
Journal:  Cancer J       Date:  2019 Mar/Apr       Impact factor: 3.360

2.  SOD2-mediated adaptive responses induced by low-dose ionizing radiation via TNF signaling and amifostine.

Authors:  J S Murley; K L Baker; R C Miller; T E Darga; R R Weichselbaum; D J Grdina
Journal:  Free Radic Biol Med       Date:  2011-09-03       Impact factor: 7.376

Review 3.  Intravital imaging of CD8+ T cell function in cancer.

Authors:  Thorsten R Mempel; Christian A Bauer
Journal:  Clin Exp Metastasis       Date:  2008-07-30       Impact factor: 5.150

4.  A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile.

Authors:  Paolo Monti; Federica Marchesi; Michele Reni; Alessia Mercalli; Valeria Sordi; Alessandro Zerbi; Giampaolo Balzano; Valerio Di Carlo; Paola Allavena; Lorenzo Piemonti
Journal:  Virchows Arch       Date:  2004-07-17       Impact factor: 4.064

5.  Requirement for tumor necrosis factor receptor 2 expression on vascular cells to induce experimental cerebral malaria.

Authors:  Benjamin Stoelcker; Thomas Hehlgans; Karin Weigl; Horst Bluethmann; Georges E Grau; Daniela N Männel
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

6.  Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium.

Authors:  Filip Van Hauwermeiren; Marietta Armaka; Niki Karagianni; Ksanthi Kranidioti; Roosmarijn E Vandenbroucke; Sonja Loges; Maarten Van Roy; Jan Staelens; Leen Puimège; Ajay Palagani; Wim Vanden Berghe; Panayiotis Victoratos; Peter Carmeliet; Claude Libert; George Kollias
Journal:  J Clin Invest       Date:  2013-05-15       Impact factor: 14.808

7.  Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy.

Authors:  H J Mauceri; M A Beckett; H Liang; H G Sutton; S Pitroda; E Galka; E Efimova; T Darga; N N Khodarev; C R King; M C Posner; S Hellman; D W Kufe; R R Weichselbaum
Journal:  Cancer Gene Ther       Date:  2008-10-31       Impact factor: 5.987

8.  IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.

Authors:  Bin Zhang; Theodore Karrison; Donald A Rowley; Hans Schreiber
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

9.  Chimeric form of tumor necrosis factor-alpha has enhanced surface expression and antitumor activity.

Authors:  R Rieger; D Whitacre; M J Cantwell; C Prussak; T J Kipps
Journal:  Cancer Gene Ther       Date:  2008-07-25       Impact factor: 5.987

10.  Thrombospondin-1-induced apoptosis of brain microvascular endothelial cells can be mediated by TNF-R1.

Authors:  Tanya A Rege; Jerry Stewart; Brian Dranka; Etty N Benveniste; Roy L Silverstein; Candece L Gladson
Journal:  J Cell Physiol       Date:  2009-01       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.